Testing for amphetamine-type stimulant (ATS) use to ascertain validity of self-reported ATS use among young female sex workers in Cambodia

Addiction Science and Clinical Practice

Volumn 7, Issue 1, 2012, Pages

  Kab, Vannda ^a   Evans, Jennifer ^b   Sansothy, Neth ^c   Stein, Ellen ^b   Claude Couture, Marie ^b   Maher, Lisa ^d,e   Page, Kimberly ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Young Women's Study Collaborative   (Cambodia)

Author keywords

Methamphetamine; Positive Urine Test; Sexually Transmit Infection; Sexually Transmit Infection Clinic; Urine Toxicology

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; CAMBODIA; CROSS-SECTIONAL STUDY; DRUG ABUSE; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVALENCE; PROSTITUTION; SELF REPORT; SENSITIVITY AND SPECIFICITY; SOCIOECONOMICS; URINE;

ADOLESCENT; ADULT; AGE FACTORS; AMPHETAMINE-RELATED DISORDERS; CAMBODIA; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HIV SEROPOSITIVITY; HUMANS; PREVALENCE; SELF REPORT; SENSITIVITY AND SPECIFICITY; SEX WORKERS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84873742823     PISSN: 19400632     EISSN: 19400640     Source Type: Journal    
DOI: 10.1186/1940-0640-7-11     Document Type: Article

References (47)

1. Mills E, Singh S, Orbinski J, Burrows D: The HIV/AIDS epidemic in Cambodia. Lancet Infect Dis. 2005, 5 (10): 596-597. 10.1016/S1473-3099(05)70222-X.
2. NCHADS: Ministry of Health National Center for HIV, AIDS, Dermatology and STDs. 2009, Annual Report, [ http://www.nchads.org/report.php ].
3. Couture MC, Sansothy N, Sapphon V, Phal S, Sichan K, Stein E, Evans J, Maher L, Kaldor J, Vun MC: Young women engaged in sex work in Phnom Penh, Cambodia, have high incidence of HIV and sexually transmitted infections, and amphetamine-type stimulant use: new challenges to HIV prevention and risk. Sex Transm Dis. 2010, 38 (1): 33-39.
4. Sopheab H, Morineau G, Neal JJ, Saphonn V, Fylkesnes K: Sustained high prevalence of sexually transmitted infections among female sex workers in Cambodia: high turnover seriously challenges the 100 % Condom Use Programme. BMC Infect Dis. 2008, 8: 167-10.1186/1471-2334-8-167.
5. Sopheab H, Saphonn V, Chhea C, Fylkesnes K: Distribution of HIV in Cambodia: findings from the first national population survey. AIDS. 2009, 23 (11): 1389-1395. 10.1097/QAD.0b013e32832cd95a.
6. Charles M: HIV epidemic in Cambodia, one of the poorest countries in Southeast Asia: a success story. Expert Rev Anti Infect Ther. 2006, 4 (1): 1-4. 10.1586/14787210.4.1.1.
7. World Health Organization Regional Office for the Western Pacific: Controlling STI and HIV in Cambodia: The success of condom promotion. [ http://www.whoint/hiv/topics/vct/sw-toolkit/controlling-sti-campdf ].
8. Sopheab H, Fylkesnes K, Vun MC, O'Farrell N: HIV-related risk behaviors in Cambodia and effects of mobility. J Acquir Immune Defic Syndr. 2006, 41 (1): 81-86. 10.1097/01.qai.0000174654.25535.f7.
9. Couture MC, Evans JL, Sothy NS, Stein ES, Sichan K, Maher L, Page K: Correlates of amphetamine-type stimulant use and associations with HIV-related risks among young women engaged in sex work in Phnom Penh, Cambodia. Drug Alcohol Depend. 2012, 120 (1-3): 119-126.
10. Maher L, Phlong P, Mooney-Somers J, Keo S, Stein E, Couture MC, Page K: Amphetamine-type stimulant use and HIV/STI risk behaviour among young female sex workers in Phnom Penh, Cambodia. Int J Drug Policy. 2011, 22 (3): 203-209. 10.1016/j.drugpo.2011.01.003.
11. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, Lecomte T: The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci. 2006, 31 (5): 301-313.
12. McKetin R, Kozel N, Douglas J, Ali R, Vicknasingam B, Lund J, Li JH: The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev. 2008, 27 (3): 220-228. 10.1080/09595230801923710.
13. Boddiger D: Metamphetamine use linked to rising HIV transmission. Lancet. 2005, 365 (9466): 1217-1218. 10.1016/S0140-6736(05)74794-2.
14. Buavirat A, Page-Shafer K, van Griensven GJ, Mandel JS, Evans J, Chuaratanaphong J, Chiamwongpat S, Sacks R, Moss A: Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: case-control study. BMJ. 2003, 326 (7384): 308-10.1136/bmj.326.7384.308.
15. Cheng WS, Garfein RS, Semple SJ, Strathdee SA, Zians JK, Patterson TL: Differences in sexual risk behaviors among male and female HIV-seronegative heterosexual methamphetamine users. Am J Drug Alcohol Abuse. 2009, 35 (5): 295-300. 10.1080/00952990902968585.
16. Cheng WS, Garfein RS, Semple SJ, Strathdee SA, Zians JK, Patterson TL: Increased drug use and STI risk with injection drug use among HIV-seronegative heterosexual methamphetamine users. J Psychoactive Drugs. 2010, 42 (1): 11-18. 10.1080/02791072.2010.10399781.
17. Colfax G, Shoptaw S: The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005, 2 (4): 194-199. 10.1007/s11904-005-0016-4.
18. Molitor F, Ruiz JD, Flynn N, Mikanda JN, Sun RK, Anderson R: Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users. Am J Drug Alcohol Abuse. 1999, 25 (3): 475-493. 10.1081/ADA-100101874.
19. Wohl AR, Johnson DF, Lu S, Jordan W, Beall G, Currier J, Simon PA: HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual. J Acquir Immune Defic Syndr. 2002, 31 (3): 354-360. 10.1097/00126334-200211010-00013.
20. United Nations Office on Drugs and Crime: Patterns and Trends of Amphetamine-Type Stimulants and Other Drugs: Asia and the Pacific. 2010, [ http://www.unodc.org/documents/scientific/ATS-Report-2010-web.pdf ].
21. National Authority for Combating Drugs: Report on Illicit Drug Data and Routine Surveillance Systems. 2007, [ http://www.unodc.org/documents/eastasiaandpacific/Publications/Projects/NACD-Annual-report2007.pdf ].
22. Dillon FR, Turner CW, Robbins MS, Szapocznik J: Concordance among biological, interview, and self-report measures of drug use among African American and Hispanic adolescents referred for drug abuse treatment. Psychol Addict Behav. 2005, 19 (4): 404-413.
23. De Irala J, Bigelow C, McCusker J, Hindin R, Zheng L: Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. Am J Epidemiol. 1996, 143 (7): 725-732. 10.1093/oxfordjournals.aje.a008806.
24. Latkin CA, Vlahov D, Anthony JC: Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction. 1993, 88 (4): 517-526. 10.1111/j.1360-0443.1993.tb02058.x.
25. Des Jarlais DC, Paone D, Milliken J, Turner CF, Miller H, Gribble J, Shi Q, Hagan H, Friedman SR: Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet. 1999, 353 (9165): 1657-1661. 10.1016/S0140-6736(98)07026-3.
26. Metzger DS, Koblin B, Turner C, Navaline H, Valenti F, Holte S, Gross M, Sheon A, Miller H, Cooley P: Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol. 2000, 152 (2): 99-106.
27. Harrison L: The validity of self-reported drug use in survey research: an overview and critique of research methods. NIDA Res Monogr. 1997, 167: 17-36.
28. Fendrich M, Johnson TP: Race/ethnicity differences in the validity of self-reported drug use: results from a household survey. J Urban Health. 2005, 82 (2 Suppl 3): iii67-iii81.
29. Fendrich M, Xu Y: The validity of drug use reports from juvenile arrestees. Int J Addict. 1994, 29 (8): 971-985.
30. Rosay AB, Najaka SS, Herz D: Differences in the validity of self-reported drug use across five factors: gender, race, age, type of drug, and offense seriousness. J of Quantitative Criminology. 2007, 23 (1): 41-58. 10.1007/s10940-006-9018-7.
31. Sherman MF, Bigelow GE: Validity of patients' self-reported drug use as a function of treatment status. Drug Alcohol Depend. 1992, 30 (1): 1-11. 10.1016/0376-8716(92)90030-G.
32. Elman I, Krause S, Breiter HC, Gollub RL, Heintges J, Baumgartner WA, Rosen BR, Gastfriend DR: The validity of self-reported drug use in non-treatment seeking individuals with cocaine dependence: correlation with biochemical assays. Am J Addict. 2000, 9 (3): 216-221. 10.1080/10550490050148044.
33. Weatherby NL, Needle R, Cesari H, Booth R, McCoy CB, Watters JK, Williams M, Chitwood DD: Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Program Plann. 1994, 17 (4): 347-355. 10.1016/0149-7189(94)90035-3.
34. Hser YI, Maglione M, Boyle K: Validity of self-report of drug use among STD patients, ER patients, and arrestees. Am J Drug Alcohol Abuse. 1999, 25 (1): 81-91. 10.1081/ADA-100101847.
35. Magura S, Kang SY: Validity of self-reported drug use in high risk populations: a meta-analytical review. Subst Use Misuse. 1996, 31 (9): 1131-1153. 10.3109/10826089609063969.
36. Hser YI: Self-reported drug use: results of selected empirical investigations of validity. NIDA Res Monogr. 1997, 167: 320-343.
37. Cook RF, Bernstein AD, Andrews CM: Assessing drug use in the workplace: a comparison of self-report, urinalysis, and hair analysis. NIDA Res Monogr. 1997, 167: 247-272.
38. Zanis DA, McLellan AT, Randall M: Can you trust patient self-reports of drug use during treatment?. Drug Alcohol Depend. 1994, 35 (2): 127-132. 10.1016/0376-8716(94)90119-8.
39. Harrison L: The validity of self-reported data on drug use. Journal of Drug Issues. 1995, 25 (1): 91-111.
40. Williams RJ, Nowatzki N: Validity of adolescent self-report of substance use. Subst Use Misuse. 2005, 40 (3): 299-311. 10.1081/JA-200049327.
41. Cook RF, Bernstein AD, Arrington TL, Andrews CM, Marshall GA: Methods for assessing drug use prevalence in the workplace: a comparison of self-report, urinalysis, and hair analysis. Int J Addict. 1995, 30 (4): 403-426.
42. Prendergast M, Podus D, Finney J, Greenwell L, Roll J: Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006, 101 (11): 1546-1560. 10.1111/j.1360-0443.2006.01581.x.
43. Lee NK, Rawson RA: A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008, 27 (3): 309-317. 10.1080/09595230801919494.
44. Rawson RA, Gonzales R, Brethen P: Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat. 2002, 23 (2): 145-150. 10.1016/S0740-5472(02)00256-8.
45. Rawson RA, Gonzales R, Marinelli-Casey P, Ang A: Methamphetamine dependence: a closer look at treatment response and clinical characteristics associated with route of administration in outpatient treatment. Am J Addict. 2007, 16 (4): 291-299. 10.1080/10550490701389864.
46. Shoptaw S, Klausner JD, Reback CJ, Tierney S, Stansell J, Hare CB, Gibson S, Siever M, King WD, Kao U: A public health response to the methamphetamine epidemic: the implementation of contingency management to treat methamphetamine dependence. BMC Publ Health. 2006, 6: 214-10.1186/1471-2458-6-214.
47. Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, Shoptaw S, Vittinghoff E: Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011, 68 (11): 1168-1175. 10.1001/archgenpsychiatry.2011.124.